Stockreport

Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]

Aytu BioPharma, Inc.  (AYTU) 
NASDAQ:AMEX Investor Relations: aytubio.com/investors/stock-information
PDF ADHD Portfolio Net Revenue: $13.2 million, compared to $13.8 million in the prior year period. Pediatric Portfolio Net Revenue: $1.7 million, up from $715,000 in the [Read more]